o2h (Group)

https://www.o2h.com

o2h Ventures Limited has launched the o2h Therapeutics and AI fund, which is the first S/EIS fund in the UK solely focused on early stage biotech therapeutics and related AI opportunities. The geographic scope shall be UK wide including Oxford and London but will target the growing Cambridge biotech cluster. The fund is structured to be S/EIS compliant providing tax breaks for UK taxpayers. The biotech sector is one of the leading sectors in the UK economy. The large pharma companies now rely on the small innovative biotechs’ for new ideas in disease areas such as cancer, genomics, anti-ageing and neurosciences amongst others which has led to higher potential exit valuations. The fund will widen the community of investors that will help expand early stage research in the UK. The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h operate from their proprietary 2.7 acre o2h SciTech Park where they are developing a unique model for incubating small life science companies. *

	Start	2019-04-01 existent
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Shah, Sunil (o2h Discovery Ltd 201806 CEO)

	Region	Cambridge, Cambridgeshire
	Country	United Kingdom (GB)
	Street	Mill Lane Mill SciTech Park, Hauxton
	City	CB22 5HX Cambridge, Cambridgeshire
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Metrion Biosciences Ltd.. (4/1/19). "Press Release: Metrion Biosciences Closes Funding Round. Includes investment from o2h Ventures Therapeutics Fund". Cambridge.

		Record changed: 2023-11-16